The stock of NanoString Technologies Inc (NASDAQ:NSTG) reached all time high today, Oct, 11 and still has $41.11 target or 92.00% above today’s $21.41 share price. This indicates more upside for the $444.21 million company. This technical setup was reported by Barchart.com. If the $41.11 PT is reached, the company will be worth $408.67M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 7,224 shares traded hands. NanoString Technologies Inc (NASDAQ:NSTG) has risen 33.33% since March 8, 2016 and is uptrending. It has outperformed by 24.02% the S&P500.
Analysts await NanoString Technologies Inc (NASDAQ:NSTG) to report earnings on November, 7. They expect $-0.51 EPS, down 4.08% or $0.02 from last year’s $-0.49 per share. After $-0.55 actual EPS reported by NanoString Technologies Inc for the previous quarter, Wall Street now forecasts -7.27% EPS growth.
According to Zacks Investment Research, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 2.52 in 2016 Q2. Its up 1.31, from 1.21 in 2016Q1. The ratio improved, as 9 funds sold all NanoString Technologies Inc shares owned while 12 reduced positions. 15 funds bought stakes while 38 increased positions. They now own 16.55 million shares or 3.90% more from 15.93 million shares in 2016Q1.
California Public Employees Retirement System, a California-based fund reported 29,000 shares. Bridgeway Cap Mngmt, a Texas-based fund reported 12,000 shares. Moreover, Dsc Limited Partnership has 3.69% invested in NanoString Technologies Inc (NASDAQ:NSTG) for 465,000 shares. Manufacturers Life Ins The holds 0% or 11,739 shares in its portfolio. Rs Mgmt Lc accumulated 27,050 shares or 0% of the stock. Millennium Mngmt Limited Liability reported 458,162 shares or 0.01% of all its holdings. Strs Ohio holds 31,900 shares or 0% of its portfolio. Barclays Public Limited holds 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG) for 306 shares. Blackrock has 759 shares for 0% of their US portfolio. Jacobs Levy Equity Management accumulated 0% or 12,800 shares. Proshare Advsrs Ltd Llc, a Maryland-based fund reported 16,568 shares. Moreover, Morgan Stanley has 0.01% invested in NanoString Technologies Inc (NASDAQ:NSTG) for 1.55 million shares. Wells Fargo & Mn holds 0% or 7,749 shares in its portfolio. Polar Capital Limited Liability Partnership has invested 0.02% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). Rhumbline Advisers, a Massachusetts-based fund reported 14,636 shares.
Insider Transactions: Since August 12, 2016, the stock had 0 insider buys, and 6 insider sales for $8.52 million net activity. WAITE CHARLES P JR sold $4.26 million worth of NanoString Technologies Inc (NASDAQ:NSTG) on Friday, August 12. 3,961 shares with value of $65,357 were sold by BURNS WAYNE on Wednesday, September 7.
NSTG Company Profile
NanoString Technologies, Inc., incorporated on June 20, 2003, develops, makes and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Firm operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Firm markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use. The Company’s molecular diagnostic product Prosigna Breast Cancer Assay, or Prosigna, provides an assessment of a patient’s risk of recurrence for breast cancer. The Firm has an installed base of over 350 systems, which its clients have used to publish more than 1,000 peer-reviewed papers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.